mTOR inhibitor temsirolimus and MEK1/2 inhibitor U0126 (cas 109511-58-2) promote chromosomal instability and cell type-dependent phenotype changes of glioblastoma cells
-
Add time:07/21/2019 Source:sciencedirect.com
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) and the RAF/mitogen-activated and extracellular signal-regulated kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathways are frequently deregulated in cancer. Temsirolimus (TEM) and its primary active metabolite rapamycin allosterically block mTOR complex 1 substrate recruitment. The context-/experimental setup-dependent opposite effects of rapamycin on the multiple centrosome formation, aneuploidy, DNA damage/repair, proliferation, and invasion were reported. Similarly, the context-dependent either tumor-promoting or suppressing effects of RAF–MEK-ERK pathway and its inhibitors were demonstrated. Drug treatment-mediated stress may promote chromosomal instability (CIN), accelerating changes in the genomic landscape and phenotype diversity. Here, we characterized the genomic and phenotypic changes of U251 and T98G glioblastoma cell lines long-term treated with TEM or U0126 (cas 109511-58-2), an inhibitor of MEK1/2. TEM significantly increased clonal and non-clonal chromosome aberrations. Both TEM and U0126 affected copy number alterations (CNAs) pattern. A proliferation rate of U251TEM and U251U0126 cells was lower and higher, respectively, than control cells. Colony formation efficiency of U251TEM significantly decreased, whereas U251U0126 did not change. U251TEM and U251U0126 cells decreased migration. In contrast, T98GTEM and T98GU0126 cells did not change proliferation, colony formation efficiency, and migration. Changes in the sensitivity of inhibitor-treated cells to the reduction of the glucose concentration were observed. Our results suggest that CIN and adaptive reprogramming of signal transduction pathways may be responsible for the cell type-dependent phenotype changes of long-term TEM- or U0126-treated tumor cells.
We also recommend Trading Suppliers and Manufacturers of U0126 (cas 109511-58-2). Pls Click Website Link as below: cas 109511-58-2 suppliers
Prev:U0126 (cas 109511-58-2) attenuates ischemia/reperfusion-induced apoptosis and autophagy in myocardium through MEK/ERK/EGR-1 pathway
Next:Antiviral activity of the MEK-inhibitor U0126 (cas 109511-58-2) against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- MEK inhibitors: The chemistry and biological activity of U0126 (cas 109511-58-2), its analogs, and cyclization products07/28/2019
- Using U0126 (cas 109511-58-2) to dissect the role of the extracellular signal-regulated kinase 1/2 (ERK1/2) cascade in the regulation of gene expression by endothelin-1 in cardiac myocytes07/27/2019
- Non-specific effects of the MEK inhibitors PD098,059 and U0126 (cas 109511-58-2) on glutamate release from hippocampal synaptosomes07/26/2019
- Prevention of LLC-PK1 cell overgrowth in a bioartificial renal tubule device using a MEK inhibitor, U0126 (cas 109511-58-2)07/25/2019
- Nociceptin and its metabolite attenuate U0126 (cas 109511-58-2)-induced memory impairment through a nociceptin opioid peptide (NOP) receptor-independent mechanism07/24/2019
- Effects of MEK-Specific Inhibitor U0126 (cas 109511-58-2) on the Conidial Germination, Appressorium Production, and Pathogenicity of Setosphaeria turcica07/23/2019
- Quantitative NMR analysis of Erk activity and inhibition by U0126 (cas 109511-58-2) in a panel of patient-derived colorectal cancer cell lines07/22/2019
- Antiviral activity of the MEK-inhibitor U0126 (cas 109511-58-2) against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo07/20/2019
- U0126 (cas 109511-58-2) attenuates ischemia/reperfusion-induced apoptosis and autophagy in myocardium through MEK/ERK/EGR-1 pathway07/19/2019